AB
AbbVie Biotech Ventures
Venture CapitalActiveAbbVie Biotech Ventures, an Illinois-based company, makes investments in emerging biotech and pharmaceutical companies.
33
Investments
5
Exits
—
AUM
15.2%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for AbbVie Biotech Ventures.
Investment Thesis & Strategy
AbbVie Biotech Ventures invests in emerging biotech and pharmaceutical companies across various stages, focusing on innovative therapies and technologies.
Investment Activity
Deals per year over the last 6 years
4
20180
20190
20203
20211
20224
2023Portfolio Companies
Selected investments from their portfolio of 33 companies
A
Acelyrin
Biotech · Series B, 2023
C
Carmot Therapeutics
Biotech · Series B, 2023
A
Apogee Therapeutics
Biotech · Series B, 2023
A
Alumis
Biotech · Series B, 2023
R
Rgenta Therapeutics
Biotech · Series A, 2022
R
Ribometrix
Biotech · Series A, 2021
N
NextPoint Therapeutics
Biotech · Series A, 2021
V
Ventyx Biosciences
Biotech · Series B, 2021
R
Revolution Medicines
Biotech · Series B, 2018
H
Harpoon Therapeutics
Biotech · Series A, 2018
K
Kezar Bio
Biotech · Series A, 2018
C
Cerevel Therapeutics
Biotech · Series A, 2018
Notable Exits
CompanyTypeYearValue / Acquirer
Tiziana Life SciencesAcquisition2024—
Revolution MedicinesIPO2020—
Harpoon TherapeuticsIPO2019—
AlectorIPO2019—
Voyager TherapeuticsIPO2017—
Frequently Asked Questions
AbbVie Biotech Ventures focuses on Series A, Series B, Series C+ stage investments.
Related Investors
Bessemer Venture Partners
Redwood City, United States · 971 deals
Threshold
Menlo Park, United States · 841 deals
Lightspeed Venture Partners
Menlo Park, United States · 839 deals
Index Ventures
San Francisco, United States · 827 deals
Andreessen Horowitz
Menlo Park, United States · 826 deals
Goldman Sachs
New York, United States · 780 deals